Gemdale USA Corp. has secured a 535,000-square-foot lease with biopharmaceutical company Neurocrine Biosciences at Aperture Del Mar in San Diego. Neurocrine will relocate its headquarters office to the property in 2023.

Neurocrine is one of San Diego's largest life science companies. Aperture was an ideal site to accommodate the company's headquarters. At the property, Neurocrine will be able to double its lab space, occupying four buildings with an option to expand into a fifth building which can offer up to another 125,000 square feet.

Aperture Del Mar is located on 15.72 acres in Del Mar Heights.  Gemdale USA Corp. acquired the property from Lincoln Property Company in October 2019, and began developing the site within a month. Phase 1, which Neurocrine will occupy, was built on spec and completed in 2019. According to Gemdale USA's managing director of development Josh Goldman, the lease illustrates the strength of the life science sector in San Diego. JLL's Chad Urie and Grant Schoneman represented Neurocrine Biosciences, while Tony Russell of JLL represented Gemdale USA Corporation in the deal.